(Q30838723)

27 June 2017

1 reference

title

Carbamazepine for schizophrenia and schizoaffective psychoses (English)

1 reference

27 June 2017

0 references

1 reference

S Leucht

1

1 reference

27 June 2017

J McGrath

series ordinal

2

1 reference

27 June 2017

P White

series ordinal

3

1 reference

27 June 2017

W Kissling

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

2000

0 references

published in

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

2

0 references

page(s)

CD001258

1 reference

Carbamazepine maintenance treatment in outpatient schizophrenics

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A double-blind trial of carbamazepine in negative symptom schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine in the psychiatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Pediatric psychopharmacotherapy: a review of recent research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine in treatment of violent schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Exacerbation of psychosis after discontinuation of carbamazepine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine for the violent psychiatric patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Review: treatment of schizophrenia. State of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A Comparison of Carbamazepine Divitabs and a Normal Carbamazepine Preparation in Psychiatric and Oligophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Drug strategies and treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Open clinical trial of carbamazepine in chronic schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Meta-analysis. Unresolved issues and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Dosage of haloperidol for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine-induced changes in plasma levels of neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine for withdrawal pseudohallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine as an adjunct of antipsychotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

The drug-drug interaction effects of haloperidol on plasma carbamazepine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Mood disorders in the psychoneurologic borderland: three cases of responsiveness to carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Response of functional hallucinations to carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Acute psychosis with carbamazepine and sodium valproate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Interaction between carbamazepine and bromperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine in the treatment of catatonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine adjunct for nonresponsive psychosis with prior hallucinogenic abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

A carbamazepine trial in chronic, treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Evidence of ten psychotic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

Carbamazepine augmentation for schizophrenia: how good is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258

10.1002/14651858.CD001258

21 January 2018

Identifiers

DOI

1 reference

release_47fnotxam5hgfcwqpzvlyb2kcm

27 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/47fnotxam5hgfcwqpzvlyb2kcm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference